Published in J Zhejiang Univ Sci B on August 08, 2017
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol (1983) 6.27
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation (2006) 5.58
Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol (2010) 3.45
Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev (2005) 3.30
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation (2001) 2.53
The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol (2015) 2.48
Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res (2003) 2.44
Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res (2001) 2.38
Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation (2003) 2.26
Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation (2013) 2.22
Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 2.18
Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation (2001) 2.13
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation (2004) 1.91
IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol (2004) 1.61
Atherosclerosis and extracellular matrix. J Atheroscler Thromb (2003) 1.35
Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.35
A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol (2011) 1.23
Evidence for altered interleukin 18 (IL)-18 pathway in human heart failure. FASEB J (2004) 1.22
Production of matrix metalloproteinases in response to mycobacterial infection. Infect Immun (2001) 1.17
Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol (2010) 1.11
Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis (2011) 0.98
The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett (2004) 0.96
MMP-1 serum levels predict coronary atherosclerosis in humans. Cardiovasc Diabetol (2009) 0.96
Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases. Curr Top Med Chem (2012) 0.93
The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol (2002) 0.91
Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics (1998) 0.87
Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis (2005) 0.87
Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. Arterioscler Thromb Vasc Biol (2015) 0.86
Plasma MMP-9 - a marker of carotid plaque instability. Eur J Vasc Endovasc Surg (2001) 0.85
The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol (2007) 0.83
Using plasma matrix metalloproteinase-9 and monocyte chemoattractant protein-1 to predict future cardiovascular events in subjects with carotid atherosclerosis. Atherosclerosis (2013) 0.82
Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat Med (2015) 0.81
Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clin Chem (2006) 0.80
Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79 years: a nested case-control study. Cytokine (2012) 0.78
Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor. Cardiovasc Res (2015) 0.75